Just as fluid biomarkers for amyloidosis and tau have revolutionized clinical studies of Alzheimer’s disease, α-synuclein markers are poised to do the same for Parkinson’s. With the advent of ...
One of the things that makes developing effective treatments for Parkinson's disease so challenging is its complexity. While some forms are caused by genetics, others have environmental factors, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback